Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease
Reports have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-α agents under clinical remis...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2016/1467583 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309103081390080 |
|---|---|
| author | Akihiro Nakamura Tomoya Miyamura Eiichi Suematsu |
| author_facet | Akihiro Nakamura Tomoya Miyamura Eiichi Suematsu |
| author_sort | Akihiro Nakamura |
| collection | DOAJ |
| description | Reports have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-α agents under clinical remission. A 31-year-old patient with vasculo-BD was initially treated with a high dose of steroid and intravenous cyclophosphamide therapy. Six months later, however, the disease recurred. IFX was administered and immediately the disease activity was reduced. Fortunately, we could discontinue IFX after 18-month remission and no recurrence has been observed. Based on previous reports and our patient, all patients who could discontinue IFX sustained clinical remission for at least one year, continued taking immunosuppressive agents such as methotrexate and azathioprine, and had vascular involvements only in non-life-threatening major vessels such as leg or arm arteries/veins. This is a report suggesting the possibility of discontinuation of IFX in vasculo-BD. |
| format | Article |
| id | doaj-art-0cb119e26b9d494ca57a0237cde855e7 |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-0cb119e26b9d494ca57a0237cde855e72025-08-20T03:54:15ZengWileyCase Reports in Rheumatology2090-68892090-68972016-01-01201610.1155/2016/14675831467583Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet DiseaseAkihiro Nakamura0Tomoya Miyamura1Eiichi Suematsu2Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka 810-8563, JapanDepartment of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka 810-8563, JapanDepartment of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka 810-8563, JapanReports have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab (IFX) can dramatically suppress the disease activity of refractory vasculo-Behçet disease (vasculo-BD). However, it is completely unknown whether we can discontinue anti-TNF-α agents under clinical remission. A 31-year-old patient with vasculo-BD was initially treated with a high dose of steroid and intravenous cyclophosphamide therapy. Six months later, however, the disease recurred. IFX was administered and immediately the disease activity was reduced. Fortunately, we could discontinue IFX after 18-month remission and no recurrence has been observed. Based on previous reports and our patient, all patients who could discontinue IFX sustained clinical remission for at least one year, continued taking immunosuppressive agents such as methotrexate and azathioprine, and had vascular involvements only in non-life-threatening major vessels such as leg or arm arteries/veins. This is a report suggesting the possibility of discontinuation of IFX in vasculo-BD.http://dx.doi.org/10.1155/2016/1467583 |
| spellingShingle | Akihiro Nakamura Tomoya Miyamura Eiichi Suematsu Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease Case Reports in Rheumatology |
| title | Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease |
| title_full | Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease |
| title_fullStr | Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease |
| title_full_unstemmed | Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease |
| title_short | Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease |
| title_sort | successful discontinuation of infliximab in a refractory case of vasculo behcet disease |
| url | http://dx.doi.org/10.1155/2016/1467583 |
| work_keys_str_mv | AT akihironakamura successfuldiscontinuationofinfliximabinarefractorycaseofvasculobehcetdisease AT tomoyamiyamura successfuldiscontinuationofinfliximabinarefractorycaseofvasculobehcetdisease AT eiichisuematsu successfuldiscontinuationofinfliximabinarefractorycaseofvasculobehcetdisease |